Scientific deep-dive

Surgery Versus GLP-1 Drugs: Reading an Indirect Comparison

A network meta-analysis of 30 trials put surgery about 10 points ahead on total weight loss. Nobody was randomized to surgery versus a drug, and against tirzepatide alone the difference vanished.

By Nora Bissett · Pricing Editor
Editorially reviewed. Not medical advice · How we verify contentLast reviewed
6 min read·1 citation

A 2026 network meta-analysis of 30 randomized trials in 20,015 people compared bariatric surgery against GLP-1 drugs, and reported that surgery produced about 10 percentage points more total weight loss. Two things about that finding matter more than the number: nobody was randomized to surgery versus a drug, and against tirzepatide alone the difference disappeared.[1]

First, how the comparison was made

This is not a trial of surgery against drugs. No such trial is in the analysis. What exists is trials of surgery against lifestyle intervention, and trials of GLP-1 drugs against lifestyle intervention. A network meta-analysis uses that shared comparator as a bridge and estimates the surgery-versus-drug comparison indirectly.

The authors state it plainly: all comparisons between surgery and GLP-1 drugs were indirect.[1] That is a legitimate and widely used method, and it carries an assumption that has to be true for the answer to hold: that the people in the surgery trials and the people in the drug trials were similar enough that a shared comparator connects them fairly.

That assumption is doing heavy lifting here. People enrolled in bariatric surgery trials tend to be heavier and to have exhausted other options; people in drug trials are often earlier in that journey. Where the populations differ, an indirect comparison inherits the difference and reports it as a treatment effect.

What was reported

Estimated treatment differences, surgery against GLP-1 receptor agonists as a class. All indirect.
OutcomeUnder 104 weeks104 weeks and beyond
Percent total weight loss−10.3% (p=0.001)−9.1% (p=0.022)
Body weight−11.7 kg (p<0.001)−14.6 kg (p=0.049)
BMI−4.5 kg/m² (p<0.001)—
Waist circumference−12.6 cm (p<0.001)—
HbA1c−0.5% (p=0.033)—

Read as a class comparison, surgery wins on every measure, and the gap persists past two years. Among participants with type 2 diabetes, surgery produced greater reductions in BMI, weight, waist and total weight loss, with similar HbA1c improvement.[1]

The row that changes the story

In tirzepatide-only analyses, differences versus surgery were not significant.

“GLP-1 receptor agonists” as a class includes liraglutide and other older drugs that produce far less weight loss than the current ones. Averaging them together produces a class figure that no modern patient is being offered. When the comparison is restricted to tirzepatide, the surgical advantage stops being statistically distinguishable.[1]

The authors’ own summary reflects this: surgery remains superior, and tirzepatide is a promising nonsurgical option. Both halves of that sentence are load-bearing, and coverage tends to quote only the first.

Cost is the axis this comparison leaves out, and a separate study puts two-year spending at $63,483 for medication against $51,794 for surgery. The operation is paid for once; the prescription is paid for every month. That study’s weight figures are much weaker than its cost figures; the weight comparison used 257 people explains why.

What weight loss does not settle

  • Surgery is permanent; a drug stops when you stop paying. Our maintenance article covers what discontinuation does, and it is the single largest practical difference between these options.
  • Surgery carries operative risk and drugs carry chronic side effects. Neither appears in a weight-loss percentage, and weight lost is not always the outcome that matters. In a small study of fertility-sparing endometrial cancer treatment, the surgery group lost the most weight and had the lowest tumor remission rate, probably because of who was steered to surgery.
  • The operation itself varies. An endoscopic sleeve, stitched through the mouth, produces less weight loss than a surgical sleeve, with fewer complications.
  • Nutritional consequences differ enormously. Bypass procedures create lifelong absorption issues that a drug does not.
  • Access differs. Surgery is a one-time approval fight; a drug is a recurring one, every month, indefinitely.

One caveat arrived after this was written. A real-world study of 44,025 people found surgery two to three times better than these drugs in ordinary care, because trial adherence and real adherence are different things (see what these drugs do outside a trial). Under trial conditions the comparison above holds, and the two are now close enough to be a real choice for some people, which was not true five years ago. In ordinary care, surgery still comes out well ahead. Our article on weight regain after surgery covers the case where someone ends up needing both.

Frequently Asked Questions

On weight loss as a class comparison, yes. A network meta-analysis of 30 trials estimated about 10 percentage points more total weight loss with surgery, sustained past two years. But when the comparison was restricted to tirzepatide, the difference was no longer statistically significant.
No. All comparisons between surgery and GLP-1 drugs in this analysis were indirect. Both were compared against lifestyle intervention, and the network connected them through that shared comparator. It is a legitimate method, and it is not a head-to-head trial.
Because the class average includes older, weaker drugs such as liraglutide that produce much less weight loss. Averaging them together produces a figure no current patient is offered. Restricted to tirzepatide alone, the surgical advantage stopped being statistically distinguishable.
Most of what matters practically: surgery is permanent while a drug stops working when you stop taking it, surgery carries operative risk while drugs carry chronic side effects, bypass procedures create lifelong nutritional consequences, and the access fights are shaped completely differently.
It is increasingly common, particularly where weight returns after surgery. That specific situation has its own evidence, which we cover separately.

References

  1. 1.Sabatella L, Ortega PM, Azcárate VV, et al. Comparative Efficacy of Metabolic/Bariatric Surgery Versus GLP-1 Receptor Agonists: A Network Meta-Analysis of Randomized Controlled Trials Obesity. 2026. PMID: 41326176.

Where to get tirzepatide online, safely: sellers our editors have checked

These are telehealth sellers our editors have checked. For each one we hold a price, the form the drug comes in, and the states it reaches.

No insurance needed · vetted by our editors

Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more

7.3

Found

People who want clinician visits billed to commercial insurance, with compounded medication in the plan price

9.1

Collective

From $69/mo + membership

Get started →
Read full review →

About this analysis

GLP Watchdog publishes independently. Each seller in our dataset is checked against that seller's own website, and the dataset is updated continuously. Read our full methodology →